+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07776210

Randomized, Double-Masked Study Evaluating Safety and Efficacy of d-MAPPS Eye Drops for Chronic Ocular Graft-Versus-Host Disease

Led by Regenerative Ocular Immunobiologics LLC · Updated on 2026-11-03

30

Participants Needed

5

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the d-MAPPS Ophthalmic Solution in adults with chronic ocular graft-versus-host disease oGVHD, a condition affecting the eyes after stem cell transplantation. This Phase III clinical trial evaluates the safety, effectiveness, and tolerability of this eye treatment compared to a placebo. The study is randomized, double-masked, and vehicle-controlled to ensure unbiased results. Participants will receive either the d-MAPPS Ophthalmic Solution or a matching placebo, both administered as two drops in each eye four times daily for 90 consecutive days. The primary evaluation occurs at Day 90, with co-primary endpoints focused on changes in corneal staining and ocular surface disease symptoms. The study also measures multiple secondary outcomes related to eye health and symptom improvement. During the trial, participants will attend study visits to assess eye condition changes using various scales and scores, including the Modified Oxford Corneal Staining Score and the Ocular Surface Disease Index. Researchers will monitor for safety, treatment response, and use of rescue therapies. Participants must comply with study visits and treatment for the full 90-day period, with the primary assessment completed at Day 90 plus or minus 15 days.

CONDITIONS

Brief Title

Study of d-MAPPS™ Ophthalmic Solution in Adults With Chronic Ocular Graft-Versus-Host Disease (oGVHD)

Research Team

M

Marissa Harrell, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here